DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2016" report to their offering.
Systemic Idiopathic Juvenile Arthritis pipeline therapeutics constitutes close to 12 molecules. which approximately 12 molecules are developed by Companies.
Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Systemic Idiopathic Juvenile Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Systemic Idiopathic Juvenile Arthritis Systemic onset juvenile idiopathic arthritis (also known as Systemic juvenile idiopathic arthritis (sJIA)) is a disorder featuring inflammation, characterized by high spiking fevers, salmon-colored rash that comes and goes, and arthritis. Symptoms are extreme fatigue accompanied by high fevers that rise daily to 102 F (39 C) or even higher and rapidly return to normal levels or below. Fever spikes often occur at approximately the same time every day.
A faint salmon colored skin rash characteristically comes and goes and does not itch. Poor appetite, nausea, and weight loss are common. There is also commonly swelling of the lymph glands, enlargement of the spleen and liver, and sore throat. Some patients develop inflammation around the heart (pericarditis) and lungs (pleuritis), with occasional fluid accumulation around heart (pericardial effusion) and lungs (pleural effusion). The molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 1, 6 and 2 respectively.
Furthermore, this report also reviews key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and discontinued projects.
- Alteogen Inc.
- Bristol-Myers Squibb Company
- Epirus Biopharmaceuticals, Inc.
- Johnson & Johnson
- Momenta Pharmaceuticals, Inc.
- Mycenax Biotech Inc.
- Novartis AG
- Oncobiologics, Inc.
For more information visit http://www.researchandmarkets.com/research/clfgh7/systemic